TuisAZN • STO
add
AstraZeneca plc
Vorige sluiting
kr 1 462,50
Dagwisseling
kr 1 443,50 - kr 1 470,50
Jaarwisseling
kr 1 261,00 - kr 1 799,00
Markkapitalisasie
208,82 mjd USD
Gemiddelde volume
443,34 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
LON
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Inkomste | 13,56 mjd | 18,04% |
Bedryfskoste | 7,79 mjd | 4,64% |
Netto inkomste | 1,43 mjd | 4,00% |
Netto winsgrens | 10,53 | -11,96% |
Wins per aandeel | 1,04 | 20,23% |
EBITDA | 4,63 mjd | 45,69% |
Effektiewe belastingkoers | 21,61% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 4,93 mjd | -3,62% |
Totale bates | 104,92 mjd | 9,20% |
Totale aanspreeklikheid | 64,12 mjd | 8,92% |
Totale ekwiteit | 40,80 mjd | — |
Uitstaande aandele | 1,55 mjd | — |
Prys om te bespreek | 55,67 | — |
Opbrengs op bates | 7,92% | — |
Opbrengs op kapitaal | 11,38% | — |
Kontantvloei
Netto kontantverandering
(USD) | Sep. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 1,43 mjd | 4,00% |
Kontant van bedrywe | 3,38 mjd | 8,64% |
Kontant van beleggings | -1,51 mjd | -24,00% |
Kontant van finansiering | -4,13 mjd | -51,54% |
Netto kontantverandering | -2,24 mjd | -163,15% |
Beskikbare kontantvloei | 2,05 mjd | -12,38% |
Meer oor
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, United Kingdom; Gothenburg, Sweden and Gaithersburg in Maryland, U.S.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
Gestig
06 Apr. 1999
Hoofkwartier
Webwerf
Werknemers
89 900